Sanofi is making a €300 million investment in Chinese biotech Innovent as part of a collaboration to bring two new cancer therapies as quickly as possible to patients in the world's second-
The FDA has dropped a bomb on Eli Lilly's marketing application for cancer immunotherapy sintilimab ahead of an advisory committee meeting due to take place on Thursday.
Eli Lilly made a late entry into the checkpoint inhibitor market when it licensed ex-China rights to Innovent's sintilimab last year, and a new trial in lung cancer will raise its hopes of
The FDA has accepted Eli Lilly and China’s Innovent filing for their latecomer immunotherapy sintilimab, which is expected to compete on price with rivals such as Merck & Co’s Keytruda.
Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be la
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.